Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Trimmed by Everett Harris & Co. CA

Everett Harris & Co. CA decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,097 shares of the medical equipment provider’s stock after selling 1,130 shares during the period. Everett Harris & Co. CA’s holdings in Zimmer Biomet were worth $4,113,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ZBH. ST Germain D J Co. Inc. boosted its holdings in shares of Zimmer Biomet by 4.6% during the third quarter. ST Germain D J Co. Inc. now owns 95,730 shares of the medical equipment provider’s stock valued at $10,334,000 after acquiring an additional 4,218 shares during the period. Blue Trust Inc. lifted its holdings in Zimmer Biomet by 165.3% in the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after purchasing an additional 1,071 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Zimmer Biomet by 1.5% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 22,230 shares of the medical equipment provider’s stock worth $2,400,000 after purchasing an additional 337 shares during the period. Trust Co. of Vermont lifted its holdings in Zimmer Biomet by 29.5% in the third quarter. Trust Co. of Vermont now owns 2,487 shares of the medical equipment provider’s stock worth $268,000 after purchasing an additional 566 shares during the period. Finally, Culbertson A N & Co. Inc. lifted its holdings in Zimmer Biomet by 10.5% in the third quarter. Culbertson A N & Co. Inc. now owns 5,813 shares of the medical equipment provider’s stock worth $628,000 after purchasing an additional 550 shares during the period. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ZBH. Morgan Stanley reduced their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Evercore ISI reduced their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Raymond James dropped their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. UBS Group lowered their price target on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Finally, Wolfe Research began coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $123.74.

Zimmer Biomet Trading Up 1.3 %

Shares of NYSE ZBH traded up $1.36 during midday trading on Friday, reaching $106.31. The company had a trading volume of 1,081,686 shares, compared to its average volume of 1,484,901. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm’s fifty day moving average price is $108.11 and its 200-day moving average price is $112.42. The stock has a market cap of $21.87 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 1.93 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the prior year, the company posted $1.82 EPS. Zimmer Biomet’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.98 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.